PERPHENAZINE DIMALEATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H26ClN3OS.2C4H4O4
Molecular Weight	636.113
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1

InChI

InChIKey=HYYMPXVEPSKZOU-SPIKMXEPSA-N

InChI=1S/C21H26ClN3OS.2C4H4O4/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26;2*5-3(6)1-2-4(7)8/h1-2,4-7,16,26H,3,8-15H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-

HIDE SMILES / InChI

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	C21H26ClN3OS
Molecular Weight	403.969
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf | http://apm.amegroups.com/article/view/1039/1266

Perphenazine is a relatively high potency phenothiazine that blocks dopamine 2 receptors predominantly, but also may possess antagonist actions at histamine 1 and cholinergic M1 and alpha 1 adrenergic receptors in the vomiting center leading to reduced nausea and vomiting. The drug was approved by FDA for the treatment of schizophrenia and control of severe nausea and vomiting (either alone or in combination with amitriptyline hydrochloride). Perphenazine is extensively hepatic to metabolites via sulfoxidation, hydroxylation, dealkylation, and glucuronidation; primarily metabolized by CYP2D6 to N-dealkylated perphenazine, perphenazine sulfoxide, and 7-hydroxyperphenazine (active metabolite with 70% of the activity of perphenazine) and excreted in the urine and feces.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
D(2) dopamine receptor 58 Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2778	0.16 nM [Ki]
Histamine H1 receptor 315 Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2778	8.0 nM [Kd]
Muscarinic acetylcholine receptor M1 169 Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2778	1.5 µM [Kd]
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://apm.amegroups.com/article/view/1039/1266	Antagonist 2778	10.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Nausea 63 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Preventing	Approved 8429	PERPHENAZINE Approved Use Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date 5.873472E11
Vomiting 38 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Preventing	Approved 8429	PERPHENAZINE Approved Use Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date 5.873472E11
Schizophrenia 298 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Primary	Approved 8429	PERPHENAZINE Approved Use Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date 5.873472E11
Anxiety 267 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2937445-c015-c9a5-52f8-a2959da97290	Primary	Approved 8429	PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE Approved Use Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Launch Date 5.9512318E11
Depression 235 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2937445-c015-c9a5-52f8-a2959da97290	Primary	Approved 8429	PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE Approved Use Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Launch Date 5.9512318E11

C_max

Value	Dose	Analyte	Population
509 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	7-HYDROXYPERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.546 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
984 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
6.673 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:		PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
18.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	7-HYDROXYPERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
9.12 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
12 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PERPHENAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% DRUG LABEL https://www.glowm.com/resources/glowm/cd/pages/drugs/p024.html	unknown, unknown		PERPHENAZINE unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) triazolam, p.o(14 mg; single) salicylate Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	Disc. AE: QT interval prolonged, Hypothermia... AEs leading to discontinuation/dose reduction: QT interval prolonged Hypothermia Loss of consciousness PR interval prolonged QRS prolonged Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104	unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104	Disc. AE: Coma, Hypothermia... AEs leading to discontinuation/dose reduction: Coma Hypothermia Tachycardia Miosis Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104
30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3	Disc. AE: Tardive dyskinesia... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3
30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4	Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4
64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3	Disc. AE: Tardive dyskinesia... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3
64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4	Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4
20 mg single, intramuscular Studied dose Dose: 20 mg Route: intramuscular Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/	unhealthy n = 1 Health Status: unhealthy Condition: Schizophrenia Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/	Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/

AEs

AE	Significance	Dose	Population
Hypothermia	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) triazolam, p.o(14 mg; single) salicylate Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631
Loss of consciousness	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) triazolam, p.o(14 mg; single) salicylate Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631
PR interval prolonged	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) triazolam, p.o(14 mg; single) salicylate Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631
QRS prolonged	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) triazolam, p.o(14 mg; single) salicylate Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631
QT interval prolonged	Disc. AE	0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) triazolam, p.o(14 mg; single) salicylate Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631	unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/21264008 Page: p.2627, 2631
Coma	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104	unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104
Hypothermia	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104	unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104
Miosis	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104	unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104
Tachycardia	Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104	unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1729053 Page: p.104
Tardive dyskinesia	Disc. AE	30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3
Neuroleptic malignant syndrome	Disc. AE	30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4
Tardive dyskinesia	Disc. AE	64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.3
Neuroleptic malignant syndrome	Disc. AE	64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4	unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf Page: p.4
Neuroleptic malignant syndrome	Disc. AE	20 mg single, intramuscular Studied dose Dose: 20 mg Route: intramuscular Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/	unhealthy n = 1 Health Status: unhealthy Condition: Schizophrenia Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3588517/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	inhibitor 1767	substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 810 CYP1A2 1524 CYP2C19 1478 CYP3A 214 P-gp 1461 UGT2B10 25 K+ channels 70 Nav1.5 97	P-gp 1537 CYP2C19 991	MRP1 48

Drug as perpetrator

Target	Modality	Activity
CYP2C19 1553	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	no
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	no
CYP3A 298	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	no
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	yes [IC50 1.5 uM]
K+ channels 70	inhibitor 3277 Sources: https://link.springer.com/article/10.1007/s00210-009-0420-1 Page: abstract	yes [IC50 38.2 uM]
UGT2B10 27	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/44/3/378.short Page: 42.0	yes [IC50 66.2 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract	yes [Ki 65.1 uM]
MRP1 172	inducer 1573 Sources: https://iv.iiarjournals.org/content/23/6/943.short Page: 945.0	yes
P-gp 1650	inhibitor 3277 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 962.0	yes

Drug as victim

Target	Modality	Activity
CYP2C19 991	substrate 3367 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 961.0	yes
CYP2D6 1217	substrate 3367 Sources: https://journals.sagepub.com/doi/abs/10.1177/0269881104047278 Page: 510.0	yes
CYP3A4 1737	substrate 3367 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 961.0	yes
P-gp 1537	substrate 3367 Sources: https://link.springer.com/article/10.1007%2Fs40263-012-0008-z Page: 961.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 100	inhibitor 1626 Sources: https://www.sciencedirect.com/science/article/pii/S0002914917310421 Page: 1033.0
hERG 1647	inhibitor 1626 Sources: https://www.tandfonline.com/doi/abs/10.1081/DCT-200064482 Page: abstract

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8028	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8028
ChemicalBook	CB6687009	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6687009
MolPort	MolPort-001-727-942	https://www.molport.com/shop/molecule-link/MolPort-001-727-942
ZINC	ZINC000019228902	http://zinc15.docking.org/substances/ZINC000019228902
eMolecules	593689	https://www.emolecules.com/cgi-bin/more?vid=593689

PubMed

Title	Date	PubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.	1967	4383787
Side-effects of phenothiazines.	1967 Apr 1	6021008
Phenothiazines in early labour.	1967 Feb 11	6017500
Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients.	1967 Mar-Apr	5336562
Dystonic reaction to perphenazine.	1969 Aug 9	4184245
Iatrogenic epilepsy due to antidepressant drugs.	1969 Oct 11	5823053
The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine.	1974	4477392
[Psychometric effects of perphenacine below the "neuroleptic threshold" (author's transl)].	1975 Dec	1233531
Asymptomatic idiopathic syndrome of prolonged Q-T interval in a 45-year-old woman. Ventricular tachyarrhythmias precipitated by hypokalemia and therapy with amitriptyline and prephenazine.	1977 Feb	832494
Metoclopramide and dystonic reactions in Sardinians.	1979 Jun 23	87799
Toxic psychosis with cimetidine.	1979 May	434259
Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.	1981	6794071
Tricyclic antidepressants and alcoholic blackouts.	1981 Jun	7229637
Dose-response relationships of perphenazine in the treatment of acute psychoses.	1982	6817364
Cerebellar syndrome following neuroleptic induced heat stroke.	1983 Feb	6842224
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.	1986	2880362
A case of progressive hemichorea responsive to high-dose reserpine.	1986 Mar	3949727
D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.	1992	1365866
Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.	1997 Dec 1	9386853
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.	1998 Oct	9766782
Perphenazine-induced hiccups.	1999 Mar	10333169
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Role of adenosine in drug-induced catatonia in mice.	2002 Aug	12597016
Drug-induced toxic myocarditis.	2003	12638679
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003 Jun	12711835
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.	2003 Mar	12629531
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.	2004 Apr 27	15109398
An unexpected increase of troponin I after perphenazine depot injection.	2004 Feb	14742781
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.	2005 May	15821958
Nerve growth factor mRNA expression in the regenerating antler tip of red deer (Cervus elaphus).	2007 Jan 10	17215957
Clinical characteristics and psychopathological profile of patients with vulvodynia: an observational and descriptive study.	2008	18032895
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.	2008 Dec	18493746
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.	2010 Apr 11	20097249
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.	2010 Feb 23	20142494

Patents

Sample Use Guides

In Vivo Use Guide

Moderately disturbed nonhospitalized patients with schizophrenia: 4 to 8 mg t.i.d. initially; reduce as soon as possible to minimum effective dosage. Hospitalized patients with schizophrenia: 8 to 16 mg b.i.d. to q.i.d.; avoid dosages in excess of 64 mg daily. Severe nausea and vomiting in adults: 8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable.

Route of Administration: Oral

In Vitro Use Guide

Perphenazine (10-100 microM) was administered, either alone or combined with dopamine, to primary mouse neuronal or intact brain culture and to a human neuroblastoma (NB) cell line (SK-N-SH). Cell viability (measured by neutral red and alamar blue), DNA fragmentation (flow cytometry-NB) were determined. Neuroblastoma: perphenazine decreased viability by 87%.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:26:50 UTC 2023` Edited by `admin` on `Sat Dec 16 01:26:50 UTC 2023`
Record UNII	7K96LZ09JI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PERPHENAZINE DIMALEATE

Common Name

English

1-PIPERAZINEETHANOL, 4-(3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)PROPYL)-, (2Z)-2-BUTENEDIOATE (1:2) (SALT)

Systematic Name

English

Perphenazine maleate [WHO-DD]

Common Name

English

PERPHENAZINE MALEATE

Common Name

English

Code System Code Type Description

CAS

3534-08-5